Biotech entity
pharma is the sole category represented across all 2 tracked stories. Eli Lilly and Company is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. This profile follows 2 Biotech stories mentioning Securities and Exchange Commission across the period from February 28, 2026 to March 3, 2026.
Last mentioned: Jun 28, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. Eli Lilly and Company is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. This profile follows 2 Biotech stories mentioning Securities and Exchange Commission across the period from February 28, 2026 to March 3, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Securities and Exchange Commission. Shared-story counts are live from our verified record — not editorial picks.
Fisher Asset Management LLC expanded its position in Eli Lilly and Company by 3.5% during the third quarter, acquiring an additional 150,595 shares. This move brings the firm's total holdings to approximately 4.45 million shares, signaling continued institutional confidence in the pharmaceutical giant's growth trajectory.
Essex Woodlands Management Inc. reduced its position in EyePoint Pharmaceuticals by 7.3% during the third quarter, selling 85,000 shares. Despite the reduction, the firm maintains a high-conviction $15.45 million stake, representing 5% of its total investment portfolio.
Securities and Exchange Commission is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
